The WHO 2022 classification redefined DHL-BCL6 as DLBCL-NOS, which was confirmed by our results that DHL/THL show a higher frequency of EZH2 mutation and possess a worse prognosis than DHL-BCL6. This evidence concerns the gene BCL6 and diffuse large B-cell lymphoma.